


The meriT-V Study

Study Highlights

- Principal Investigator: Dr. Alexandre Abizaid
- The meriT-V is a prospective, multicentre, randomized, open-label, non-inferiority trial of the BioMime sirolimus-eluting coronary stent system (SES) as compared to the XIENCE family of everolimus-eluting coronary stents (EES) in the treatment of patients with de novo native coronary artery lesions
- Two-year clinical follow-up including angiographic analysis at 9-month
- BioMime SES was non-inferior to XIENCE EES for the primary endpoint of in-stent late lumen loss



❖ Study Design

A prospective, multicentre, randomized, open-label, active-controlled, non-inferiority trial



256 patients were enrolled and randomly assigned (2:1) to BioMime SES or XIENCE EES between November 2014 and December 2016



15 investigational sites in Europe (12 sites, including the Netherlands, Belgium, UK, Spain, Latvia, FYR of Macedonia, Czech Republic, and Poland) and Brazil (3 sites)



Clinical follow-up at 30-day, 5-month, 9-month, 12-month and 24-month post-procedure



Angiographic follow-up at 9-month
Analysed by Cardiovascular Research Centre, Sao Paulo, Brazil

❖ Study Results




Figure1: Late Lumen Loss at 9-month Follow-up




Figure 2: Cumulative event curve of MACE




Figure 3: Cumulative event curve of MI




Figure 4: Cumulative event curve of ID-TVR

❖ References

1. ClinicalTrials.gov – NCT02112981 at <https://clinicaltrials.gov/ct2/show/NCT02112981>
2. Presented as an Educational interview by Alexandre Abizaid. Evidences from the meriT-V randomized trial on BioMime SES and from MeRes-1 Extend, MeRes100 BRS 1st in man evaluation, At Euro PCR 2017; <https://www.pconline.com/Cases-resources-images/Resources/Educational-interviews/Evidences-from-the-meriT-V-randomized-trial-on-BioMime-SES-and-from-MeRes-1-Extend-MeRes100-BRS-1st-in-man-evaluation?auth=true>.
3. Presented by Ricardo A. Costa. My Experience with BioMime SES & meriT-V RCT Update, At TCT-2017; <http://www.chungtuo.com/modules/news/article.php?storyid=38>
4. Abizaid AA, Kedev S, Kedhi E, Talwar S, Erglis A, Hlinomaz O, et al. Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial. *EuroIntervention*. 2018;14(11):e1207-e14.
5. Abizaid A, Costa R, Botelho R, et al. TCT-664 Twelve-Month Clinical Outcomes Comparing Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Coronary Stents in Patients With De Novo Native Coronary Artery Lesions: The meriT-V Randomized Trial. *Journal of the American College of Cardiology*. 2018;72(13 Supplement):B265.
6. Bangalore S, Toklu B, Patel N, Feit F, Stone GW. Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease. *Circulation*. 2018;138(20):2216-26.
7. Presented by Ricardo Costa. Twelve-Month Clinical Outcomes Comparing Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Coronary Stents in Patients With De Novo Native Coronary Artery Lesions: The meriT-V Randomized Trial, At TCT-2018.
8. Presented by Alexandre Abizaid. BioMime- Thinner strut DES & meriT- V RCT update, At TCT-2018.
9. Presented by Teguh Santosa. BioMime SES Vs Xience EES Randomized Clinical Trial –meriT-V & Future DES Direction, At India Live 2018.
10. Presented by Alexandre Abizaid. meriT-V: One-year clinical outcomes of sirolimus eluting coronary stent system (BioMime SES) in comparison with Everolimus eluting coronary stent system (XIENCE V) in randomized controlled study, At Euro PCR 2018; <http://www.crtonline.org/presentation-detail/merit-v-one-year-clinical-outcomes-of-sirolimus-el>.
11. Presented by Alexandre Abizaid. One-year clinical outcomes of randomised controlled study meriT-V of sirolimus-eluting coronary stent system in comparison with everolimus-eluting coronary stent system, At Euro PCR 2018.